View Cart (0 items)
Renal News / Clinical / Top News Stories / Abbott / Dialysis Business

Abbott partner halts CKD study

October 23, 2012
/ Print / Reprints /
| Share More
/ Text Size+

Abbott shares fell 3.5% when it announced its partner Reata Pharmaceuticals announced it would halt a clinical study of bardoxolone methyl in patients with stage 4 chronic kidney disease and type 2 diabetes.

Reata said in a statement that the decisions was made based upon a recommendation of the Independent Data Monitoring Committee to stop the trial "for safety concerns due to excess serious adverse events and mortality in the bardoxolone methyl arm."

You must login or register in order to post a comment.